Novavax Highlights Positive Results From Partner's Clinical Trial of Vaccine Using Matrix-M(TM)
- Genocea Biosciences' Herpes Simplex Therapeutic Vaccine uses Matrix-M adjuvant
- Phase 1/2A U.S.-based clinical trial enrolled 143 volunteers with moderate-to-severe HSV-2
- Two highest dose Matrix-M adjuvanted cohorts demonstrated statistically significant reductions in viral shedding
- Genocea's Phase 2 planned for 2014
Genocea's results showed that vaccination with GEN-003 potentiated by the Matrix-M adjuvant can significantly blunt HSV-2 infection and reduce viral shedding. The two highest dose cohorts, both adjuvanted with Matrix-M, demonstrated significant reductions in viral shedding (51% and 30%, respectively, each p<0.001). No serious adverse events were related to the vaccine.
The partnership agreement with Genocea covers the use of Matrix-M in the development of vaccines against specific diseases including herpes simplex virus type 2.
"The strong showing of Genocea's vaccine candidate, which includes our proprietary adjuvant Matrix-M, underscores the potential of the adjuvant to
"The early clinical response to GEN-003 in this trial is unprecedented in HSV-2. We are proud to be pioneers in the field of T cell-directed vaccines," noted
To read Genocea's published press release, follow the link:
Matrix-M is a patented vaccine adjuvant being developed and produced by
Herpes simplex virus type 2 (HSV-2), the most common cause of genital herpes, is a sexually transmitted disease that is estimated to infect more than 500 million people worldwide, and one out of six people aged 14 to 49. In the U.S., an estimated 50-60 million people are affected. HSV-2 infection can cause recurring, painful genital sores and, due to the stigma associated with this disease, can impact patients' ability to form and maintain relationships, resulting in considerable psychological distress in patients. No vaccine is currently approved to prevent or treat the disease.
About Genocea Biosciences
Genocea Biosciences is harnessing the power of T cell immunity to develop the next generation of vaccines. T cells are increasingly recognized as a critical element of a protective immune response to a wide range of infectious disease pathogens, but are difficult to target using traditional vaccine discovery methods. Genocea is uniquely able to identify protective T cell antigens in humans exposed to a pathogen using ATLAS™, its proprietary technology platform that mimics the human immune response in the laboratory, potentially improving the effectiveness of vaccine candidates and drastically reducing the time needed to create them. Genocea's pipeline of novel T cell vaccines includes GEN-003 for HSV-2 therapy, GEN-004, a protein vaccine directed at pneumococcus that is expected to enter the clinic in the fourth quarter of 2013, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria.
Statements herein relating to the future of
Barclay PhillipsSVP, Chief Financial Officer and Treasurer Novavax, Inc.240-268-2000